At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single-arm clinical trial of atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, as first-line or subsequent therapy for patients with locally advanced or metastatic PD-L1-selected non-small cell lung cancer.
BIRCH: Phase 2 trial of atezolizumab for advanced PD-L1-selected non-small cell lung cancer
9th December 2015
Oncology
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now